Published in Curr Neuropharmacol on November 26, 2015
Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science (1992) 4.58
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest (2003) 3.41
Neuroinflammation in Alzheimer's disease. Lancet Neurol (2015) 3.02
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Molecular cloning and nucleic acid binding properties of the GAP-associated tyrosine phosphoprotein p62. Cell (1992) 2.32
Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke (2002) 2.13
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest (2006) 2.10
Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer (2013) 1.92
Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene (2004) 1.80
Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J (2004) 1.79
Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci (2000) 1.72
Molecular mechanisms of early brain injury after subarachnoid hemorrhage. Neurol Res (2006) 1.64
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol (2005) 1.63
Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci (2009) 1.58
Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One (2013) 1.57
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One (2009) 1.55
Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler (2009) 1.50
Astrocytes in Alzheimer's disease. Neurotherapeutics (2010) 1.47
Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem (2006) 1.44
Subarachnoid haemorrhage: difficulties in diagnosis and treatment. Postgrad Med J (1998) 1.44
Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol (2002) 1.35
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs (2010) 1.34
Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis (2010) 1.26
Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta (2010) 1.24
EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med (2011) 1.16
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. J Neuroimmunol (2009) 1.15
Identification of signaling components required for the prediction of cytokine release in RAW 264.7 macrophages. Genome Biol (2006) 1.14
Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol (2003) 1.14
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One (2009) 1.11
Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia (2007) 1.06
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther (2009) 1.05
Src and the control of cell division. Bioessays (1996) 1.04
Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res Ther (2014) 1.03
Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. Acta Neurol Scand (2004) 1.02
Platelet-derived growth factor-mediated signal transduction underlying astrocyte proliferation: site of ethanol action. J Neurosci (1999) 1.01
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol (2010) 1.01
Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis. J Immunol (2009) 1.00
Altered subcellular distribution of c-Abl in Alzheimer's disease. J Alzheimers Dis (2009) 0.99
GATA2 and Sp1 positively regulate the c-kit promoter in mast cells. J Immunol (2010) 0.99
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. J Neuroinflammation (2012) 0.98
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer (2009) 0.98
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol (2012) 0.97
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther (2011) 0.96
Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol (2013) 0.95
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy (2009) 0.94
Beta-amyloid protein (25-35) disrupts hippocampal network activity: role of Fyn-kinase. Hippocampus (2010) 0.93
Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging (2011) 0.91
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol (2011) 0.91
Post-injury treatment with 7,8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. PLoS One (2014) 0.91
HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-PI3K/Akt signaling pathway in stroke. Brain Res (2014) 0.88
Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia. J Pharmacol Exp Ther (2009) 0.86
Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci (2014) 0.86
Imatinib buys time for brain after stroke. Nat Med (2008) 0.85
Imatinib mesylate: an innovation in treatment of autoimmune diseases. Recent Pat Inflamm Allergy Drug Discov (2013) 0.84
Exploiting the promiscuity of imatinib. J Biol (2009) 0.82
Endothelial nitric oxide synthase regulates white matter changes via the BDNF/TrkB pathway after stroke in mice. PLoS One (2013) 0.81
Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.80
Imatinib preserves blood-brain barrier integrity following experimental subarachnoid hemorrhage in rats. J Neurosci Res (2014) 0.80
Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iran J Allergy Asthma Immunol (2014) 0.80
Update on lymphocyte specific kinase inhibitors: a patent survey. Expert Opin Ther Pat (2010) 0.79
Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathol Commun (2014) 0.78
Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia. Mult Scler (2013) 0.77
Neuropilin-1 enforces extracellular matrix signalling via ABL1 to promote angiogenesis. Biochem Soc Trans (2014) 0.77
Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats. Acta Neurochir Suppl (2013) 0.76
Altered expression of c-Abl in patients with epilepsy and in a rat model. Synapse (2014) 0.75
Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.80
Cell-penetrating peptides modulate the vascular action of phenylephrine. Pharmacol Rep (2011) 0.77
Antiplatelet effect of statins is augmented in diabetic rabbits. Pharmacol Rep (2010) 0.75